Brilliance Licensed to Phoenix Medical Systems
We are happy to announce that we have signed an unprecedented licensing agreement with Chennai, India-based Phoenix Medical Systems for the manufacturing and distribution of Brilliance! This deal marks the first time that an American nonprofit will receive licensing fees and royalties for its technology from an Indian for-profit company in the healthcare industry. With this process complete, we are one step further towards the goal of our Neonatal Jaundice Initiative—ending morbidity and mortality related to newborn jaundice.
Together, D-Rev and Phoenix have agreed to cap Brilliance’s price tag at $400 per device so that it remains affordable in emerging and undercapitalized markets. Although Brilliance is low-cost, laboratory trials conducted at Stanford Medical School have shown that the device outperforms comparable Western devices that cost upwards of $3,000. Phoenix will manufacture, distribute and sell Brilliance exclusively in India and non-exclusively in much of the rest of the world.
It is generally held that a purely for-profit company can’t viably serve poor patients in developing countries, while the more common donation or subsidy model often results in a product that few people use. In combining both business models, our partnership ensures that a life-saving medical product gets to the hospitals where it is most needed. The D-Rev—Phoenix licensing agreement is structured to incentivize sales to public hospitals in India and low-income countries.
“Our partnership with D-Rev represents innovation not only in the medical device field, but in bridging continents and sectors,” V. Sashi Kumar, the managing director of Phoenix, expressed. “Our organizations are highly complementary in that we can leverage our individual strengths and collective networks to ensure that no child is at risk of death or disability from an easily treatable condition.”
Every year, at least 12 million newborns worldwide require phototherapy to treat severe jaundice, a condition caused by neonatal hyperbilirubinemia. More than 5 million children per year do not receive the treatment they need, in large part due to a lack of affordable, effective treatment devices. With the help of our partners, including the Stanford School of Medicine, the Hasso-Plattner Institute of Design at Stanford University, the Mulago Foundation, the National Collegiate Inventors and Innovators Alliance, our awesome volunteers, and the hard-working fellows at Eastwick, we can begin reversing those trends and saving lives.
Update: Click here to read coverage of the deal in Fast Company.